With this agreement in place, Efemia will soon be available to buy from three major pharmacy companies in Sweden, as similar agreement have already been signed with Apoteket AB and Apotek Hjärtat.

"We are excited about this agreement with Apotea regarding the inclusion of Efemia in their assortment. This agreement will make Efemia even more visible and available for Swedish women with stress urinary incontinence (SUI)," says Invent Medic’s CEO Karin Bryder.

Karin Bryder is satisfied with the company’s success when it comes to signing agreements and initiating collaborations for Efemia in Sweden since the market launch in the fall of 2018. Today, the product is available both through the public healthcare system and private entities.

"With Apotea included, we now have agreements with three major pharmacy companies and seven healthcare regions in Sweden. We also have a very successful collaboration with the non-profit women’s health organisation 1.6 & 2.6 million club. Our joint campaigns and lectures have contributed to that many Swedish women with SUI have discovered Efemia and are now able to life a more active and healthy life."

Efemia’s availability in Sweden
Apoteket AB (in 33 pharmacies and on apoteket.se)
Apotek Hjärtat (apotekhjartat.se)
Apotea (www.apotea.se from the summer of 2020)
Region Jämtland Härjedalen
Region Norrbotten (via Onemed)
Region Blekinge (from October 2020)
Region Kronoberg (from October 2020)
Region Värmland
Västra Götalandsregionen

Efemia’s availability in international markets
Belgium
Denmark
Germany
The Netherlands (approved for subscription with cost coverage)
Norway (approved for prescription with cost coverage)
The UK (approved for prescription with cost coverage in England)

 

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

This information is information that Invent Medic Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on July 3, 2020.

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.